



A service of the National Library of Medicine
and the National Institutes of Health

My NCBI
[Sign In] [Register]

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search for

Limits Preview/Index History Clipboard Details

Display Show Sort by Send to

About Entrez

All: 46 Review: 45

Text Version

Items 1 - 20 of 46

Page of 3 Next

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation

Matcher

Batch Citation

Matcher

Clinical Queries

Special Queries

LinkOut

My NCBI

Related

Resources

Order Documents

NLM Mobile

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

☐ 1: Senties-Gomez MD, Galvez-Gastelum FJ, Meza-Garcia E, Armendariz-Borunda J. Related Articles, Links

☐ [Hepatic fibrosis: role of matrix metalloproteinases and TGFbeta] Gac Med Mex. 2005 Jul-Aug;141(4):315-22. Review. Spanish. PMID: 16164129 [PubMed - indexed for MEDLINE]

☐ 2: Naito Y, Yoshikawa T. Related Articles, Links

☐ Role of matrix metalloproteinases in inflammatory bowel disease. Mol Aspects Med. 2005 Aug-Oct;26(4-5):379-90. Review. PMID: 16112187 [PubMed - indexed for MEDLINE]

☐ 3: Hijova E. Related Articles, Links

☐ Matrix metalloproteinases: their biological functions and clinical implications. Bratisl Lek Listy. 2005;106(3):127-32. Review. PMID: 16026148 [PubMed - indexed for MEDLINE]

☐ 4: Emonard H, Bellon G, de Diesbach P, Mettlen M, Hornebeck W, Courtoy PJ. Related Articles, Links


☐ Regulation of matrix metalloproteinase (MMP) activity by the low-density lipoprotein receptor-related protein (LRP). A new function for an "old friend". Biochimie. 2005 Mar-Apr;87(3-4):369-76. Review. PMID: 15781324 [PubMed - indexed for MEDLINE]

☐ 5: Davidson B, Reich R, Risberg B, Nesland JM. Related Articles, Links

☐ The biological role and regulation of matrix metalloproteinases (MMP) in cancer. Arkh Patol. 2002 May-Jun;64(3):47-53. Review. PMID: 15338725 [PubMed - indexed for MEDLINE]

☐ 6: Beaudeau JL, Giral P, Bruckert E, Foglietti Related Articles, Links

MJ, Chapman MJ.

-  Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives.

Clin Chem Lab Med. 2004 Feb;42(2):121-31. Review.

PMID: 15061349 [PubMed - indexed for MEDLINE]

- ☐ **7:** Lambert E, Dasse E, Haye B, Petitfrere E. Related Articles, Links

-  TIMPs as multifacial proteins.

Crit Rev Oncol Hematol. 2004 Mar;49(3):187-98. Review.

PMID: 15036259 [PubMed - indexed for MEDLINE]

- ☐ **8:** Watanabe N, Ikeda U. Related Articles, Links

-  Matrix metalloproteinases and atherosclerosis.

Curr Atheroscler Rep. 2004 Mar;6(2):112-20. Review.

PMID: 15023295 [PubMed - indexed for MEDLINE]


- ☐ **9:** Lindsey ML. Related Articles, Links

-  MMP induction and inhibition in myocardial infarction.

Heart Fail Rev. 2004 Jan;9(1):7-19. Review.

PMID: 14739764 [PubMed - indexed for MEDLINE]

- ☐ **10:** Maskos K, Bode W. Related Articles, Links

-  Structural basis of matrix metalloproteinases and tissue inhibitors of metalloproteinases.


Mol Biotechnol. 2003 Nov;25(3):241-66. Review.

PMID: 14668538 [PubMed - indexed for MEDLINE]

- ☐ **11:** Cataldo DD, Gueders MM, Rocks N, Related Articles, Links

Sounni NE, Evrard B, Bartsch P, Louis R,

Noel A, Foidart JM.

-  Pathogenic role of matrix metalloproteases and their inhibitors in asthma and chronic obstructive pulmonary disease and therapeutic relevance of matrix metalloproteases inhibitors.

Cell Mol Biol (Noisy-le-grand). 2003 Sep;49(6):875-84. Review.

PMID: 14656045 [PubMed - indexed for MEDLINE]

- ☐ **12:** Chakraborti S, Mandal M, Das S, Mandal Related Articles, Links


A, Chakraborti T.

-  Regulation of matrix metalloproteinases: an overview.

Mol Cell Biochem. 2003 Nov;253(1-2):269-85. Review.

PMID: 14619979 [PubMed - indexed for MEDLINE]

- ☐ **13:** Nagase H, Brew K. Related Articles, Links

-  Designing TIMP (tissue inhibitor of metalloproteinases) variants that are selective metalloproteinase inhibitors.

Biochem Soc Symp. 2003;(70):201-12. Review.

PMID: 14587293 [PubMed - indexed for MEDLINE]

- ☐ **14:** Bode W, Maskos K. [Related Articles](#), [Links](#)



Structural basis of the matrix metalloproteinases and their physiological inhibitors, the tissue inhibitors of metalloproteinases.

Biol Chem. 2003 Jun;384(6):863-72. Review.

PMID: 12887053 [PubMed - indexed for MEDLINE]

- ☐ **15:** Beaudeau JL, Giral P, Bruckert E, Foglietti MJ, Chapman MJ. [Related Articles](#), [Links](#)



[Matrix metalloproteinases and atherosclerosis. Therapeutic aspects]

Ann Biol Clin (Paris). 2003 Mar-Apr;61(2):147-58. Review. French.

PMID: 12702469 [PubMed - indexed for MEDLINE]

- ☐ **16:** Vilcinskas A, Wedde M. [Related Articles](#), [Links](#)



Insect inhibitors of metalloproteinases.

IUBMB Life. 2002 Dec;54(6):339-43. Review.

PMID: 12665244 [PubMed - indexed for MEDLINE]

- ☐ **17:** Bloomston M, Zervos EE, Rosemurgy AS [Related Articles](#), [Links](#)
2nd.



Matrix metalloproteinases and their role in pancreatic cancer: a review of preclinical studies and clinical trials.

Ann Surg Oncol. 2002 Aug;9(7):668-74. Review.

PMID: 12167581 [PubMed - indexed for MEDLINE]

- ☐ **18:** Nagase H, Brew K. [Related Articles](#), [Links](#)



Engineering of tissue inhibitor of metalloproteinases mutants as potential therapeutics.

Arthritis Res. 2002;4 Suppl 3:S51-61. Epub 2002 May 9. Review.

PMID: 12110123 [PubMed - indexed for MEDLINE]

- ☐ **19:** D'Armiento J. [Related Articles](#), [Links](#)



Matrix metalloproteinase disruption of the extracellular matrix and cardiac dysfunction.

Trends Cardiovasc Med. 2002 Apr;12(3):97-101. Review.

PMID: 12007733 [PubMed - indexed for MEDLINE]

- ☐ **20:** Yoshizaki T, Sato H, Furukawa M. [Related Articles](#), [Links](#)



Recent advances in the regulation of matrix metalloproteinase 2 activation: from basic research to clinical implication (Review).

Oncol Rep. 2002 May-Jun;9(3):607-11. Review.

PMID: 11956636 [PubMed - indexed for MEDLINE]

Items 1 - 20 of 46

Page 1 of 3 Next

Display Show Sort by Send to [Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)[Department of Health & Human Services](#)[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Nov 15 2005 04:49:13



A service of the National Library of Medicine
and the National Institutes of Health

www.pubmed.gov

My NCBI

[\[Sign In\]](#) [\[Register\]](#)

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search for

[Limits](#) [Preview/Index](#) [History](#) [Clipboard](#) [Details](#)

Display Show Sort by Send to

[About Entrez](#)

All: 1 Review: 1

[Text Version](#)

☐ 1: [Enzyme Protein](#). 1996;49(1-3):7-19.

[Related Articles, Links](#)

[Entrez PubMed](#)

[Overview](#)

[Help | FAQ](#)

[Tutorial](#)

[New/Noteworthy](#)

[E-Utilities](#)

[PubMed Services](#)

[Journals Database](#)

[MeSH Database](#)

[Single Citation](#)

[Matcher](#)

[Batch Citation](#)

[Matcher](#)

[Clinical Queries](#)

[Special Queries](#)

[LinkOut](#)

[My NCBI](#)

[Related](#)

[Resources](#)

[Order Documents](#)

[NLM Mobile](#)

[NLM Catalog](#)

[NLM Gateway](#)

[TOXNET](#)

[Consumer Health](#)

[Clinical Alerts](#)

[ClinicalTrials.gov](#)

[PubMed Central](#)

MMP-2: expression, activation and inhibition.

Corcoran ML, Hewitt RE, Kleiner DE Jr, Stetler-Stevenson WG.

Extracellular Matrix Pathology Section, National Cancer Institute,
National Institutes of Health, Bethesda, Md., USA.

Remodeling of the extracellular matrix (ECM), which occurs during many physiological and pathological processes, is one of the requisite events of cellular invasion. The matrix metalloproteinases (MMPs) are a family of zinc-dependent proteases that are responsible for proteolytic degradation of specific ECM components. Regulating the activity of the MMPs at both mRNA and/or protein levels modulates the degradation of the ECM components which in turn alter cellular invasion. Although most MMPs are regulated via similar mechanisms at the mRNA and protein levels, the modulation of gelatinase A is unique. Understanding the mechanisms that regulate gelatinase A is important since expression and activation of this particular MMP is consistently correlated with a majority of malignant phenotypes. In this report, we will contrast the mechanisms that regulate the expression, activation and inhibition of gelatinase A with the mechanisms that modulate the rest the MMP family.

Publication Types:

- [Review](#)
- [Review, Tutorial](#)

PMID: 8796994 [PubMed - indexed for MEDLINE]

Display Show Sort by Send to

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Nov 15 2005 04:49:13

low-to-moderate levels of TIMP2 promote the activation of MMP2, whereas higher levels inhibit its activation by saturating free MT-MMPs that are needed to remove the MMP2 prodomain (Strongin et al. 1995). TIMP2 protein levels are reduced and MMP2 activation is enhanced in the presence of the MMP2 substrate, type IV collagen (Maquoi et al. 2000). Furthermore, the ability of collagen to induce MMP2 activation on demand probably results from TIMP2 degradation because there are no accompanying changes in MMP2, MT1-MMP, or TIMP2 mRNA expression or in the synthesis or activation of MT1-MMP. Therefore, local accumulation of type IV collagen may trigger its own degradation by somehow lowering local TIMP2 concentrations to levels that favor MMP2 activation.

Endogenous Metalloproteinase Inhibitors

The TIMPs represent a family of at least four 20–29-kDa secreted proteins (TIMPs 1–4) that reversibly inhibit the MMPs in a 1:1 stoichiometric fashion (reviewed in Edwards 2001, Sternlicht & Werb 1999, Gomez et al. 1997). They share 37–51% overall sequence identity, a conserved gene structure, and 12 similarly separated cysteine residues. These invariant cysteines form six intrachain disulfide bridges to yield a conserved six-loop, two-domain structure. Truncated “tiny” TIMPs 1 and 2 retain their inhibitory activity despite containing only the first three loops, thus indicating that portions of the N-terminal domain interact with the MMP catalytic site (Murphy & Willenbrock 1995). Mutational analyses (O’Shea et al. 1992, Willenbrock & Murphy 1994, Huang et al. 1997) and peptide- and antibody-blocking experiments (Bodden et al. 1994) have helped to further specify which regions of the N-terminal domain influence inhibitory function. In addition, NMR (Williamson et al. 1997) and X-ray crystallographic studies (Gomis-Rüth et al. 1997) have revealed which TIMP residues interact directly with the MMP3 catalytic domain and how they inhibit MMP activity. Although these studies indicate that the inhibitory activity of the TIMPs resides almost entirely in the N-terminal domain alone, both domains influence enzyme-inhibitor binding (Willenbrock & Murphy 1994). For example, the C-terminal domain (loops 4–6) of TIMP1 binds the hemopexin domain of MMP9 more readily than it does the hemopexin domain of MMP2, whereas the C-terminal domain of TIMP2 preferentially binds the hemopexin domain of MMP2 (Murphy & Willenbrock 1995).

Individual TIMPs differ in their ability to inhibit various MMPs (reviewed in Woessner & Nagase 2000). For example, TIMP2 and TIMP3 inhibit MT1-MMP, whereas TIMP1 does not. Likewise, TIMP1 is a relatively poor inhibitor of MT3-MMP, and TIMP3 appears to be a more potent inhibitor of MMP9 than other TIMPs. TIMP3 is also unique in its ability to inhibit ADAMs-10 and -17, ADAMTS-4, and ADAMTS-5 (Kashiwagi et al. 2001), whereas TIMP1 can inhibit ADAMTS-1 (Tortorella et al. 1999). In addition, the TIMPs differ in terms of their gene regulation and tissue-specific patterns of gene expression (Edwards 2001). TIMP3 also has the unique ability to bind via its C-terminal domain to heparan sulfates proteoglycans within the ECM, thereby concentrating it to specific regions within tissues and basement membranes (Langton et al. 1998).